SGLT2i and GLP1-RA are now recommended for use in all people with T2D with atherosclerotic CVD or at high risk of CVD, heart failure or chronic kidney disease, irrespective of glycated haemoglobin (HbA1c) or metformin use [3]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.